Osimertinib in Elderly Patients — What Changes and What to Watch

No. NCCN and ESMO guidance does not recommend a different starting dose for older patients. Dose changes are made when side effects occur or when a specific health condition — such as severe liver impairment — makes a change clinically appropriate. Age as a number alone is not one of those reasons.

Osimertinib can affect the electrical activity of the heart in a proportion of patients, so your team will check an ECG before you start and at intervals during treatment. If you have a known heart rhythm problem or a history of QT prolongation, tell your oncologist before your first dose. In many cases treatment can still go ahead with careful monitoring and coordination with your cardiologist.

Mild to moderate liver impairment does not routinely require a dose adjustment. Severe liver impairment changes how the body breaks down osimertinib, and ESMO guidance indicates these patients need closer monitoring. Your oncologist will review your liver function results before starting and at regular intervals, and will adjust your dose if those results change significantly.

Mild to moderate kidney disease does not typically change the osimertinib dose. The medicine is not primarily cleared by the kidneys, so kidney function has less influence on how the drug behaves than liver function does. Your team will still monitor your kidney function as part of routine blood tests. If your kidney function is severely reduced, discuss this with your oncologist before starting.

Pre-existing lung conditions, including interstitial lung disease or scarring, increase the risk of a treatment-related lung reaction called pneumonitis. This does not automatically mean osimertinib cannot be used, but your team will review your baseline scans carefully and watch closely for symptoms. If you develop any new breathlessness, a dry cough, or fever, contact your team the same day rather than waiting for a scheduled appointment.

Medicines that strongly activate the CYP3A4 enzyme — including some used for epilepsy, tuberculosis, and fungal infections — can reduce the amount of osimertinib in your blood and make it less effective. St John's Wort has the same effect and should be avoided. Your oncologist will review your full medicine list before you start. Never stop or change another medicine without discussing it with your treating team first.

Older patients may be more sensitive to fatigue, which can affect balance and daily function. Diarrhoea and skin reactions — dryness, rash, nail changes — are common across all ages. The risk of a heart or lung reaction does not automatically increase with age, but it does increase if you already have an underlying heart or lung condition. Your team will tailor monitoring to your individual profile rather than applying a standard plan based on age.

Yes, and this matters more if you see several specialists for different conditions. Osimertinib interacts with a range of medicines, and any new prescription — from a cardiologist, neurologist, or general physician — should be checked against your current treatment. Carry a written record of all your medicines to every appointment. If a new medicine is being started urgently in a hospital or emergency setting, make sure the treating doctor knows you are on osimertinib.